Kinase Drug Discovery: Modern Approaches

Kinase Drug Discovery: Modern Approaches

  • 定價:14100

分期價:(除不盡餘數於第一期收取) 分期說明

3期0利率每期47006期0利率每期2350
  • 運送方式:
  • 臺灣與離島
  • 海外
  • 可配送點:台灣、蘭嶼、綠島、澎湖、金門、馬祖
  • 可取貨點:台灣、蘭嶼、綠島、澎湖、金門、馬祖
載入中...
  • 分享
 

內容簡介

Kinase inhibition remains an area of significant interest, and growing importance, across academia and the pharmaceutical industry. There are now many marketed drugs that target kinases and a significant number of compounds are currently in various stages of clinical development. This book is a forward-looking analysis of a number of key areas for kinase inhibition in the coming years and builds on the first volume. This includes topics such as screening approaches to target kinases along with different modes of inhibition such as allosteric and covalent. Novel approaches such as macrocyclisation are considered along with how the properties of kinase inhibitors have evolved, including the potential for brain penetration. Recent areas of great importance also covered include cutting edge molecular modelling approaches and the importance of kinase mutations. The evolving biology of kinases has also resulted in increased interest in the immuno-oncology area and also pseudokinases as a target family. As with the first volume the book finishes with a forward looking view of how research against this fascinating target class may evolve.

 

作者簡介

Dr Frederick W Goldberg is a Medicinal Chemist at AstraZeneca, UK. He received his MSci at Cambridge University, PhD at Imperial College London and a Postdoc (Fulbright scholarship) at the University of Texas at Austin. He has extensive experience of leading both chemistry and project teams within oncology, including targets that have delivered clinical candidates. He has over 30 published papers and patents, including a number of research papers and perspective articles on kinases. Dr Richard A Ward is a Computational Medicinal Chemist at AstraZeneca, UK. He received his BSc (Hons) in Chemistry with Bio-organic Chemistry at The University of Birmingham and gained a PhD in Computational Chemistry also at The University of Birmingham, under the supervision of Dr John Wilkie. He has extensive experience in target selection, lead generation and lead optimisation against kinase and non-kinase targets with a specialisation in covalent drug discovery. Along with publishing a number of papers on kinases, Richard is a co-inventor of the EGFR mutant kinase inhibitor osimertinib.

 

詳細資料

  • ISBN:9781788010832
  • 規格:精裝 / 413頁 / 23.4 x 16.3 x 2.8 cm / 普通級
  • 出版地:美國

最近瀏覽商品

 

相關活動

  • 21世紀的人生難題,線上解憂價,單本88折,二本85折!
 

購物說明

外文館商品版本:商品之書封,為出版社提供之樣本。實際出貨商品,以出版社所提供之現有版本為主。關於外文書裝訂、版本上的差異,請參考【外文書的小知識】。

調貨時間:無庫存之商品,在您完成訂單程序之後,將以空運的方式為您下單調貨。原則上約14~20個工作天可以取書(若有將延遲另行告知)。為了縮短等待的時間,建議您將外文書與其它商品分開下單,以獲得最快的取貨速度,但若是海外專案進口的外文商品,調貨時間約1~2個月。 

若您具有法人身份為常態性且大量購書者,或有特殊作業需求,建議您可洽詢「企業採購」。 

退換貨說明 

會員所購買的商品均享有到貨十天的猶豫期(含例假日)。退回之商品必須於猶豫期內寄回。 

辦理退換貨時,商品必須是全新狀態與完整包裝(請注意保持商品本體、配件、贈品、保證書、原廠包裝及所有附隨文件或資料的完整性,切勿缺漏任何配件或損毀原廠外盒)。退回商品無法回復原狀者,恐將影響退貨權益或需負擔部分費用。 

訂購本商品前請務必詳閱商品退換貨原則 

  • 熟年
  • dune
  • 國際書展